These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 38820324)

  • 21. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Souqiyyeh MZ; Shaheen FA
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.
    Quarles LD; Sherrard DJ; Adler S; Rosansky SJ; McCary LC; Liu W; Turner SA; Bushinsky DA
    J Am Soc Nephrol; 2003 Mar; 14(3):575-83. PubMed ID: 12595492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
    Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
    Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between reductions in parathyroid hormone and serum phosphorus during the management of secondary hyperparathyroidism with calcimimetics in hemodialysis patients.
    Cooper K; Quarles D; Kubo Y; Tomlin H; Goodman W
    Nephron Clin Pract; 2012; 121(3-4):c124-30. PubMed ID: 23208191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Slowing the progression of vascular calcification in hemodialysis.
    Chertow GM
    J Am Soc Nephrol; 2003 Sep; 14(9 Suppl 4):S310-4. PubMed ID: 12939387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients.
    Ramos AM; Albalate M; Vázquez S; Caramelo C; Egido J; Ortiz A
    Kidney Int Suppl; 2008 Dec; (111):S88-93. PubMed ID: 19034335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends in Mineral Metabolism Treatment Strategies in Patients Receiving Hemodialysis in the United States.
    Hall R; Platt A; Wilson J; Ephraim PL; Hwang AS; Chen A; Weiner DE; Boulware LE; Pendergast J; Scialla JJ;
    Clin J Am Soc Nephrol; 2020 Nov; 15(11):1603-1613. PubMed ID: 33046525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia.
    De Schutter TM; Behets GJ; Geryl H; Peter ME; Steppan S; Gundlach K; Passlick-Deetjen J; D'Haese PC; Neven E
    Kidney Int; 2013 Jun; 83(6):1109-17. PubMed ID: 23486515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conversion from Intravenous Vitamin D Analogs to Oral Calcitriol in Patients Receiving Maintenance Hemodialysis.
    Thadhani RI; Rosen S; Ofsthun NJ; Usvyat LA; Dalrymple LS; Maddux FW; Hymes JL
    Clin J Am Soc Nephrol; 2020 Mar; 15(3):384-391. PubMed ID: 32111702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.
    Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S
    Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology].
    Mazzaferro S; Cozzolino M; Marangella M; Strippoli GF; Messa P;
    G Ital Nefrol; 2007; 24 Suppl 37():S107-24. PubMed ID: 17347960
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of parathyroidectomy versus calcimimetics for secondary hyperparathyroidism and kidney transplantation: a propensity-matched analysis.
    Koh EY; van der Plas WY; Dulfer RR; Pol RA; Kruijff S; Rotmans JI; Appelman-Dijkstra N; Schepers A; de Borst MH; Hoorn EJ; van Ginhoven TM; Nieveen van Dijkum EJM; Vogt L; Engelsman AF;
    Langenbecks Arch Surg; 2020 Sep; 405(6):851-859. PubMed ID: 32778916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
    Bernardor J; De Mul A; Bacchetta J; Schmitt CP
    Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone health and vascular calcification relationships in chronic kidney disease.
    Spasovski GB
    Int Urol Nephrol; 2007; 39(4):1209-16. PubMed ID: 17899431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients.
    Mazzaferro S; Pasquali M; Farcomeni A; Vestri AR; Filippini A; Romani AM; Barresi G; Pugliese F
    Nephrol Dial Transplant; 2008 Jul; 23(7):2319-23. PubMed ID: 18281320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.
    Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP
    Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Administration of calcimimetics after dialysis: same effectiveness, better gastrointestinal tolerability.
    Esteve Simo V; Moreno-Guzmán F; Martínez Calvo G; Fulquet Nicolas M; Pou Potau M; Macias-Toro J; Duarte-Gallego V; Saurina Sole A; Ramírez-de Arellano Serna M
    Nefrologia; 2015; 35(4):403-9. PubMed ID: 26306967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
    Prajapati VA; Galani VJ; Shah PR
    Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circadian variation of mineral and bone parameters in end-stage renal disease.
    Trivedi H; Szabo A; Zhao S; Cantor T; Raff H
    J Nephrol; 2015 Jun; 28(3):351-9. PubMed ID: 25138650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.